NASDAQ : CUE
Cue Biopharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 20.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 151.61M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 144.85M |
| Enterprise Value | 130.52M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 7.26M |
| Shares Outstanding | 7.26M |
| Shares Change (YoY) | +84.06% |
| Shares Change (QoQ) | +31.90% |
| Owned by Insiders (%) | 7.34% |
| Owned by Institutions (%) | 22.71% |
| Float | 6.36M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.03 |
| Forward PS | 74.56 |
| PB Ratio | 47.25 |
| P/TBV Ratio | 65.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.25 |
| Quick Ratio | 1.07 |
| Debt / Equity | 1.33 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -508.47 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -1,603.48% |
| Return on Assets (ROA) | -172.66% |
| Return on Invested Capital (ROIC) | -395.46% |
| Return on Capital Employed (ROCE) | -1,039.56% |
| Weighted Average Cost of Capital (WACC) | 18.43% |
| Revenue Per Employee | $1.30M |
| Profits Per Employee | -$5.66M |
| Employee Count | 29 |
| Asset Turnover | 1.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 500,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.63 |
| 52-Week Price Change | -9.20% |
| 50-Day Moving Average | 25.46 |
| 200-Day Moving Average | 21.21 |
| Relative Strength Index (RSI) | 46.81 |
| Average Volume (20 Days) | 151,868 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 792,553 |
| Short Previous Month | 702,198 |
| Short % of Shares Out | 10.91% |
| Short % of Float | 12.46% |
| Short Ratio (days to cover) | 1.80 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 37.66M |
| Gross Profit | -37.34M |
| Operating Income | -98.64M |
| Pretax Income | -163.61M |
| Net Income | -164.11M |
| EBITDA | -97.28M |
| EBIT | -98.64M |
| Loss Per Share | -$36.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 17.41M |
| Total Debt | 3.08M |
| Net Cash | 14.34M |
| Net Cash Per Share | $1.97 |
| Equity (Book Value) | 2.31M |
| Book Value Per Share | 0.44 |
| Working Capital | 5.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -50.05M |
| Capital Expenditures | -121,000 |
| Depreciation & Amortization | 1.36M |
| Net Borrowing | -2.50M |
| Free Cash Flow | -50.17M |
| FCF Per Share | -$6.91 |
Margins
| Measure | Value |
|---|
| Gross Margin | -99.15% |
| Operating Margin | -261.97% |
| Pretax Margin | -434.49% |
| Profit Margin | n/a |
| EBITDA Margin | -258.36% |
| EBIT Margin | -261.97% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -84.06% |
| Shareholder Yield | -84.06% |
| Earnings Yield | -181.66% |
| FCF Yield | -33.09% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $88.00 |
| Price Target Difference | 341.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -30.10% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 24, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -32 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |